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Abstract
Candida albicans is the most common human fungal pathogen causing mucosal and systemic
infections. However, human antifungal immunity remains poorly defined. Here, by integrating
transcriptional analysis and functional genomics, we identified Candida-specific host defense
mechanisms in humans. Candida induced significant expression of genes from the type I
interferon (IFN) pathway in human peripheral blood mononuclear cells. This unexpectedly
prominent role of type I IFN pathway in anti-Candida host defense was supported by additional
evidence. Polymorphisms in type I IFN genes modulated Candida-induced cytokine production
and were correlated with susceptibility to systemic candidiasis. In in-vitro experiments, type I
IFNs skewed Candida-induced inflammation from a Th17-response toward a Th1-response.
Patients with chronic mucocutaneaous candidiasis displayed defective expression of genes in the
type I IFN pathway. These findings indicate that the type I IFN pathway is a main signature of
Candida-induced inflammation and plays a crucial role in anti-Candida host defense in humans.
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Introduction
Candida albicans (C. albicans) is a commensal microorganism that inhabits human skin and
mucosa. Candida can be isolated from up to 70% of the general population at any given
moment, and it is believed that all individuals have been colonized with Candida at a some
point1. Although it is a commensal organism, C. albicans can also cause mucosal and
systemic infections, especially in immunocompromised hosts2. Despite the availability of
novel classes of antifungal agents (e.g., azoles, echinocandins), mortality due to systemic
candidiasis, the fourth most common form of sepsis3-5, reaches 37-44%3, 6, 7. In addition,
vaginal and oral candidiasis can also occur in healthy or only mildly immunocompromised
individuals8, with up to 5% of women in the general population suffering from recurrent
vulvovaginal candidiasis9.
Despite the introduction of modern antifungal drugs and intensive care facilities, progress in
improving the outcome of Candida infections in the last decade has been disappointing.
Given this lack of progress, it is currently believed that only adjuvant immunotherapy will
be able to further reduce the burden of morbidity and mortality caused by C. albicans
infections10. Understanding the host defense pathways involved in candidiasis is therefore
crucial for identifying novel targets for immunotherapy. To date, all investigations aimed at
identifying antifungal host defense mechanisms in humans have relied on candidate-target
approaches that are based on biologic plausibility of hypotheses extracted from in vitro or
animal studies. While this approach has been fruitful in confirming important pathways of
antifungal defense, it has lacked the power to provide a hierarchy of the importance of these
pathways, and to identify potentially novel and unexpected host defense mechanisms
against Candida.
In the present study, we have taken an alternative, unbiased approach to this biological
problem. Using a combination of transcriptional analysis and systems biology, we have
stimulated human primary cells with the fungus, identifying Candida-specific transcription
profiles in human immune cells. While C. albicans induced the transcription of multiple
inflammatory gene sets commonly stimulated by other inflammatory stimuli, it also
specifically induced several additional gene sets, among which we identified an
unexpectedly strong type I IFN signature profile. We confirmed the importance of the type I
IFN pathway for anti-Candida host defense in humans through immunological and genetic
studies in both healthy volunteers and in patients with systemic candidiasis or suffering from
chronic mucocutaneous candidiasis (CMC).
RESULTS
Candida albicans induces a type I interferon response
We measured genome-wide transcriptional profiles in peripheral blood mononuclear cells
(PBMCs) from healthy volunteers upon stimulation with C. albicans, as well as with
inflammatory stimuli unrelated to fungal pathogens: Escherichia coli-derived
lipopolysaccharide (LPS), Borrelia burgdorferi, Mycobacterium tuberculosis (MTB), and
RPMI culture medium as a control. Measurements were performed at 4 and 24 hours. 693
transcripts that showed >2-fold higher expression compared to corresponding RPMI
stimulation were selected (BH-adjusted P < 0.05). K-means analysis identified profile
clusters that indicated shared and specific genes that were differentially expressed in
response to each stimulus. We grouped shared genes into signatures representing common
early response genes (clusters 1, 6, 14, 27), common late response genes (clusters 2, 3), and
common inflammatory genes induced by all stimulations (clusters 9, 21, 25) (Fig. 1a and
Supplementary Fig. S1-3).
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More importantly, to identify a set of discriminatory features (from the 693 differentially
expressed transcripts) that would be most informative of the state of Candida stimulation
and could distinguish Candida stimulation from the other inflammatory stimuli, we utilized
information gain (Kullback-Leibler divergence/relative entropy) feature selection, to reduce
the dimensionality of the feature space11, 12. We performed 10-fold cross-validation which
stratifies the data into 10 random partitions in which each (in turn) is held out for testing and
the remainder for training a Bayesian classifier. Class prediction was evaluated by
computing the area under the receiver-operating characteristic (ROC) curve (AUROC),
which assesses true- and false-positive rates. A 101-transcript (95-gene) Candida-response
signature (Fig. 1b and Supplementary Table S1) was defined using this supervised learning
approach for class prediction, achieving an AUROC of 97.8%, which would indicate an
excellent classifier performance with very high discriminative value. Principal component
analysis (PCA) of the Candida-response signature further demonstrated good class
separation on the basis of Candida status and stimulation duration (Fig. 1c). As a set, the 101
features collectively identify expression signatures that are informative of Candida
stimulation across the 4-hour, 24-hour or both time-points that sufficiently distinguish
Candida from the rest. Enrichment analysis for the 101-transcript Candida-response
signature revealed a striking over-representation of the interferon (IFN) signaling pathway
(p=3.8×10−35) (Fig. 1d and Supplementary Table S2). This set of genes was strongly
induced at both 4 hours and 24 hours of Candida stimulation and establishes a definitive
Candida-responsive signature distinct from that observed with LPS, MTB or Borrelia
stimulation.
Type I IFN SNPs modulate susceptibility to candidemia
In order to assess whether the type I IFN genes specifically induced by C. albicans in human
leukocytes are indeed involved in antifungal host defense, we investigated whether common
polymorphisms in a subset of these genes influence susceptibility to systemic Candida
infections. From a cohort of 217 Caucasian patients with candidemia, well described
elsewhere10, 13, we had Immunochip genotyping data available and 11 genes of the 101-
transcript (95-gene) dataset were covered by the Immunochip array (Supplementary Table
S3). We tested these 11 genes for association by taking immunochip data on 12,228 non-
candidemia Caucasian healthy volunteers as controls14. Analysis of the loci associated with
these 11 genes revealed significant association of genetic variation with susceptibility to
systemic candidiasis in four regions: CCL8 SNP 1kg_17_29697448 (p = 0.00069), STAT1
SNP rs16833172 (p = 0.0042), SP110 SNP rs3769845 (p = 0.012) and PSMB8 SNP
rs3198005 (p = 0.01) (Fig. 2a-d) (Supplementary Fig. S1-3, clusters 10, 11, 20, 11
respectively) (Supplementary Table S3). After applying a stringent Bonferroni correction for
multiple testing, the association between susceptibility to candidemia and STAT1 and CCL8
remained significant. This finding confirms that the C. albicans-specific genes we identified
in our transcriptional arrays play an important role in host defense against systemic fungal
infections. We also attempted to assess whether the polymorphisms in these genes also
modified disease severity. However, only 51 patients fulfilled the criteria of severe
candidiasis based on clinical scores and persistence of positive blood cultures, and this
number was too low for allowing the identification of significant differences between
genetic variation and disease severity (disseminated disease, persistent fungemia and
mortality at 14 or 30 days) (data not shown).
Type I IFN SNPs modulate Candida-induced cytokine responses
In an additional approach to validate the role of the type I IFN pathway for host defense
against Candida, we isolated PBMCs from an additional group of 74 healthy volunteers and
stimulated the cells with the fungus. Genetic variation in 11 type I IFN pathway genes
present on the Immunochip was correlated with C. albicans-induced release of TNF-α,
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IL-1β, IL-8, IL-6, IL-10, IFN-γ and IL-17. In contrast to other microbial stimuli such as
LPS and MTB, C. albicans induced higher levels of TNF-α, IL-1β and IL-10 production,
and lower levels of IL-8 and IL-6 in human PBMCs (Supplementary Fig. S4). The
correlation of cytokine concentrations with genotypes at tag SNPs of Candida-induced IFN
pathway genes revealed significant associations at IRF1 and STAT1 regions (Fig. 3a-d) in
which IRF1 SNPs were associated with TNFα (p = 0.0028) and IL-10 levels (p = 0.0024),
while STAT1 SNPs were associated with TNF-α (p = 0.001) and IL-6 levels (p = 0.0002).
Consistent with the specificity of the type I IFN pathway for Candida stimulation, the
association was significant with cytokine levels induced by Candida, but not by LPS or
MTB stimulation (Supplementary Fig. S5).
Type I IFNs skew cytokine responses from Th17 towards Th1
To investigate the importance of type I IFN signaling in host defense against Candida,
PBMCs from healthy individuals were stimulated with heat-killed C. albicans. In line with
the transcriptional profile described above (Fig. 1), IFN-β could be detected in cell culture
supernatants only after C. albicans stimulation. In contrast, neither live (Fig. 4a), nor heat-
killed C. albicans induced any detectable IFN-α production
We next assessed the role of type I IFN pathways in the induction of cytokines by C.
albicans. When PBMCs were stimulated with heat-killed C. albicans in the presence of an
antibody against IFN-α/β/ω receptor 1 (IFNAR), IFNγ production was significantly lower
compared to PBMCs stimulated in the presence of a control antibody. Blocking of IFNAR
did not influence the production of the monocyte-derived cytokines IL-β or TNF-α (Fig.
4b). Conversely, adding IFN-α or IFN-β to Candida-stimulated cells increased IFN-γ
production, while significantly decreasing IL-17 and IL-22 production (Fig. 4c). Together
these data suggest that type I interferons (in the context of infection, most likely IFN-β)
modulate the immune reaction induced by C. albicans, skewing host defense toward a Th1
response.
STAT1 mutations cause reduced expression of type I IFN genes
Patients with autosomal dominant CMC have increased susceptibility to mucosal fungal
infections and often carry gain-of-function mutations in STAT115, 16, which lead to STAT1
hyperphosphorylation, that in turn likely makes STAT1 unavailable for forming
heterodimers with other STAT molecules17. In co-cultures of DCs and T-cells from CMC
patients, this led to defective Th1 and Th17 responses (Supplementary Fig. S6). In order to
validate the role of Candida-specific genes in human antifungal mucosal defense, we
assessed the expression of these genes in cells from CMC patients. PBMCs from healthy
controls and CMC patients were stimulated with RPMI, E. coli-derived LPS, heat-killed C.
albicans, or heat-killed MTB. The expression of type I IFN pathway genes (including IRF5,
IRF7, ISG15, IFI44 and IFI44L) that are induced downstream of STAT1-STAT2 showed
patterns of defective expression in CMC patients compared to healthy controls, supporting a
role of the type I IFN pathway in this immunodeficiency (Fig. 5). The expression of IRF3,
IRF9 and IFN-β, three genes in the type I IFN pathway upstream of STAT1-STAT2, was
not decreased in cells from CMC patients. In fact, Candida induced IFN-β expression
appeared to be higher in cells from CMC patients, possibly indicating a compensatory
feedback mechanism.
In order to investigate the type I IFN pathway in CMC patients in a more systematic way,
we also performed RNA sequencing analysis in PBMCs stimulated with C. albicans from
both control volunteers and CMC patients. The differential expression of 91 genes in
response to C. albicans stimulation was compared between CMC patients and healthy
controls (10 genes from the 101-gene signature characteristic for Candida were not
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considered: 7 because another isoform was already used for FPKM calculations, and 3
hypothetical proteins without concordant refseq genes). In cells from healthy controls, two
genes showed downregulation (LFNG, RGC32), while all other genes were upregulated
upon stimulation (Supplementary Fig. S7), validating the previous findings based on
expression array analysis. In order to observe differences between patients and controls, the
standardized fold change was used to create the respective heatmap (Fig. 6). The patients
show a much lower standardized fold change in genes downstream of STAT1, again
supporting the role of type 1 IFN pathway in CMC. We found 27 genes, from the set of 91
genes, to be significantly differently regulated upon Candida stimulation in patients
compared to controls based on an ANOVA analysis (p-value interaction group and treatment
<0.05) (MX1, OAS3, IFIT2, RTP4, XAF1, OAS2, IFI44, IFIH1, IFIT3, ADAR, PRIC285,
FAM46A, SAMD9L, EIF2AK2, PARP12, TRIM22, ZBP1, HERC6, RSAD2, IFNG, OAS1,
STAT2, DHX58, IRF7, TNFSF10, ISG15, HERC5). To determine the role of these 27 genes
we calculated Gene ontology (GO) enrichment scores using the Database for Annotation,
Visualization and Integrated Discovery (DAVID). Enriched gene clusters were generated
using Functional Annotation Clustering. Gene ontology terms associated with response to
type I interferon and viral infections showed significant enrichment (p=1.09×10−14)
(Supplementary Table S4).
DISCUSSION
The last decade has witnessed a significant increase in knowledge related to the mechanisms
involved in antifungal host defense. However, most of this knowledge is based on in-vitro
and animal studies; these studies led to hypotheses to be tested in human systems, leading to
a somewhat biased view of human immunity against fungi. In the present study we have
used a different approach based exclusively on complementary human studies:
transcriptomics analysis in human primary cells, correlation of genetic variability and
antifungal immunity in healthy volunteers (functional genomics), case-control association
studies in patients with disseminated C. albicans infections, and assessment of antifungal
immunity in CMC patients.
In our initial approach, we designed a hypotheses-generating set of experiments by assessing
the transcriptional profile induced in circulating primary leukocytes by C. albicans. Human
primary PBMCs were stimulated either with C. albicans or with other inflammatory stimuli.
Pathway analysis of the genes induced by Candida indicated two broad categories: (i) a first
set of genes that was strongly induced and shared by both C. albicans and other
inflammatory stimuli (LPS, MTB, or B. burgdorferi), constituted expected pathways
involved in inflammation and innate immunity, many of which have important roles in
antifungal immunity18, and (ii) a feature set comprising an expression signature of 101
transcripts (95 genes) that distinguishes the Candida-specific response and is characterized
by a strikingly strong and unanticipated type I IFN response.
Because the identification of the type I IFN pathway as the most prominent Candida-specific
transcriptional signature was surprising, we initiated a series of studies to confirm this
finding. Firstly, we assessed whether genetic polymorphisms in several of the genes
identified in the Candida-specific dataset influenced susceptibility to systemic Candida
infections. In a cohort of patients with candidemia that were genotyped using the
Immunochip platform (Illumina14), on which 11 genes of the Candida-specific dataset were
covered, we identified significant association of genetic variation with susceptibility to
candidiasis in four of these genes: CCL8 locus, STAT1, SP110 locus, and PSMB8 locus.
This finding confirms that genes from the 101 Candida-specific dataset influence
susceptibility to systemic fungal infections.
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Secondly, the role of the type I IFN pathway for the anti-Candida immune response was
subsequently validated in a study in which PBMCs isolated from a group of healthy
volunteers were stimulated with the fungus. Genetic variation in the 11 type I IFN pathway
genes present on the Immunochip was correlated with C. albicans-induced cytokine
production. The correlation of cytokine concentrations with genotypes at tag SNPs of
Candida-induced IFN pathway genes revealed significant associations at IRF1 and STAT1
regions, both crucial components of type I IFN pathway. We cannot exclude however that
the effect of these polymorphisms on TNFα production are exerted through type II
interferons; IFNγ is stimulated by type I interferons19, and is known to induce TNF-α
production20. These data support the hypothesis of the specificity of the type I IFN pathway
for Candida stimulation, as this association was significant only for cytokine production
induced by Candida, but not by other stimuli.
Thirdly, we performed classical immunological studies to assess the role of type I IFNs for
Candida-induced immune responses, and we demonstrated that type I IFNs induced by
Candida modulate Th1/Th17 cytokine profiles; IFNα and IFNβ increased IFNγ production,
while decreasing IL-17 production. Moschen et al previously demonstrated that type I
interferons decrease IL-17 production in vitro and in vivo.21 TNF-α production did not seem
to be influenced by blocking the IFNAR, suggesting that genetic effects in STAT1 exert
their effect on TNF-α production either through direct intracellular pathways, or indirectly
through IFNγ. Interestingly C. albicans seems to induce only IFN-β, rather than IFN-α,
consistent with earlier studies in mice22, 23.
Finally, using both qPCR and RNA sequencing analysis, we demonstrated that the
expression of type I IFN pathway-induced genes was defective in CMC patients harboring a
gain of function mutation in STAT115. These mutations lead to increased STAT1
phosphorylation and IFNγ signaling. Liu et al demonstrated increased STAT1
phosphorylation in response to IFNγ stimulation in U3C cells transfected with mutated
STAT116. They hypothesize that IFN targeted genes can lead to decreased IL-17 production.
However, freshly isolated PBMC from CMC patients do not produce any IFNγ in response
to C. albicans stimulation15. Therefore, it is more likely that the inability of mutated STAT1
to form heterodimers with STAT3 and STAT4 causes defective Th1/Th17 responses17,
which are likely to represent the main immunological defect in this disease. Additional
defects in the expression of type I interferon-induced genes, as shown here, may also
contribute to the increased susceptibility to mucosal fungal infections. Whether this is truly
caused by a defect in STAT1-STAT2 heterodimerization remains to be demonstrated.
Taken together, these complementary studies represent a compelling body of evidence that
the type I IFN pathway is an important component of the immune response during infections
with C. albicans in humans. Moreover, the data presented here are supported by emerging
information from murine studies. For example, Bourgeois et al. and Biondo et al. have
reported that mouse conventional dendritic cells produce IFN-β upon stimulation with
Candida spp. and have proposed a role for MyD88, TLR7 and TLR9 in this induction22, 23.
On the other hand, these results are relatively surprising, as no earlier study has reported a
role for type I IFNs in human antifungal host defense. In this respect, primary
immunodeficiencies in type I IFN pathway are mainly associated with viral, rather than
fungal, infections24. Therefore, our data suggest that type I IFN defects determine an
increase susceptibility risk for fungal infections, as demonstrated here by the association
with candidemia in risk groups, rather than an overt immunodeficiency associated with
severe fungal infections.
The precise effect of type I IFNs for anti-Candida host defense is still being debated. One
study in type I IFNAR knockout mice suggested a deleterious role for this pathway22,
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whereas another study reported that IFNAR−/− mice die from their inability to control fungal
growth23. While type I IFNs play an important role in the immune response against viral
infections25, they seem to be deleterious in bacterial infections26. In humans with Candida
infections, the role of type 1 IFNs is not yet settled, although the defects seen in type I IFN
gene expression in CMC patients, the susceptibility to candidemia by STAT1
polymorphisms, and the potentiation of Th1 responses by type I IFNs, all suggest a
beneficial effect of the type I IFN pathway in human antifungal host defense.
Although viruses have long been known to induce type I IFN production, other
microorganisms have been recently reported to induce this pathway. MTB stimulation
induces the expression of IFNB and IFNA1 in human macrophages27 and in murine bone
marrow-derived macrophages28; type I IFNs are required for caspase-1 activation during
Francisella tularensis infection29; and Listeria monocytogenes induces the transcription of
IFNB in macrophages30. However, the complete transcriptional profile of the type I IFN
pathway performed here shows important differences from the type I IFN profile induced by
MTB 31 and is significantly more pronounced for Candida than for MTB (Supplementary
Fig. S4). Interestingly, the very strong induction of type I IFN pathway genes by Candida
may explain the well-known, yet unexplained, beneficial effects of injecting Candida-
derived extracts for the treatment of warts in patients32, 33.
In summary, this work presents complementary arguments from several studies to propose
that the type I IFN pathway plays an important role in the immune responses to the fungal
pathogen C. albicans in humans. The cross-validation between these approaches supports the
value of this systems biology approach, combining transcriptomics with functional genomics
and immunological data. Using this approach, we have confirmed the role of pathways
known to be involved in antifungal host defense (e.g., common inflammatory pathways and
the Th1/Th17 pathways) and we have identified a novel pathway (the type I IFN pathway).
It is expected that this knowledge will have an important contribution in devising novel
immunotherapeutic strategies for fungal infections, as well as influencing decision-making
for vaccine design.
METHODS
Study populations
For assessing the transcriptome and the cytokine production capacity, blood was collected
after written informed consent from healthy volunteers. Adult patients with candidemia were
enrolled after informed consent (or waiver as approved by the Institutional Review Board) at
the Duke University Hospital (DUMC, Durham, North Carolina, USA) and Radboud
University Nijmegen Medical Centre (RUNMC, Nijmegen, The Netherlands). The study
was approved by the Institutional Review Boards at each study center, and enrollment
occurred between January 2003 and January 200934. The study was performed in
accordance with the declaration of Helsinki. In addition, blood was collected from two
patients with CMC (on two different occasions) and eight healthy controls in order to
investigate the induction of IFN genes by Candida. After informed consent was given, blood
was collected by venipuncture into 10 ml EDTA syringes (Monoject, s-Hertogenbosch, The
Netherlands).
PBMC isolation
Separation and stimulation of peripheral blood mononuclear cells (PBMCs) was performed
as described previously35. Briefly, the PBMC fraction was obtained by density
centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque
(Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed twice in saline and suspended
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in culture medium. The cells were counted in a hemocytometer and their number was
adjusted to 5·106/mL.
Cell stimulation
For the transcriptome analysis, cells were stimulated for 4 or 24 hours with RPMI, heat-
killed Borrelia burgdorferi36, Candida albicans (UC 820)(1·106/mL)37, Mycobacterium
tuberculosis (1 μg/mL) or E. coli-derived LPS (10 ηg/mL). In order to correlate cytokine
production to SNPs in the type I IFN pathway, 5×105 PBMCs from healthy volunteers were
stimulated with heat-killed C. albicans (1·106/mL) for 24 hours. In order to investigate the
effect of type I IFNs on cytokine production, 5×105 PBMCs were stimulated with heat-
killed C. albicans (1·106/mL) in the absence or presence of IFN-α2b (1·105 U/mL)(IntronA,
SP Labo N.V., Heist-op-den-berg, Belgium), IFN-β (10 ng/mL), or anti-IFNAR (100 ηg/
mL)(21385-1, PBL Inferon Source, Piscataway, USA). To assess the development of Th1
and Th17 cells, a total of 1×106 mononuclear cells was added to 96-wells flat-bottom plates
(Greiner). Subsequently, the monocytes within the PBMC pool were differentiated towards
dendritic cells (DCs) by addition of IL-4 (50 ng/ml, R&D Systems), GM-CSF (50 ng/ml,
R&D Systems) and 10% human serum for seven days. After every second day, half of the
medium was replaced by fresh DC differentiation medium. At day seven of the culture, cells
were stimulated with 1×106Candida conidia for another six days.
Transcriptome analysis
Global gene expression was profiled using Illumina Human HT-12 Expression BeadChip
according to manufacturer’s instructions. Image analysis, bead-level processing and quantile
normalization of array data were performed using the Illumina LIMS platform, BeadStudio.
A gene-wise linear model was fitted to the data and was performed in R programming
language (http://www.r-project.org/), utilizing functions from Linear Models for Microarray
Data38. For each probe, a moderated t-statistic (with standard errors moderated across genes)
was computed using a Bayesian model. The associated p values were adjusted to control the
false discovery rate in multiple testing, using the Benjamini and Hochberg’s (BH) method39.
For each transcript, Signal-to-Noise ratios (SNR) were computed for each infection or
stimuli group relative to the untreated (RPMI) control group. The expression SNR profiles
of transcripts identified as differentially expressed (BH-adjusted p<0.05 and fold-
change>2x) were clustered using the K-means algorithm40. We performed feature (attribute)
selection41, 42 on differentially expressed transcripts using Information Gain (Kullback-
Leibler divergence or relative entropy) to identify discriminatory features or transcripts that
are most informative of the state of infection or stimulation. The accuracy of class prediction
using a Java implementation of a naïve Bayes classifier42, 43 incorporating these features
was evaluated using 10-fold cross-validation.
Cytokine measurements
The concentration of IL-1β, IL-17, IL-22, TNF-α (R&D Systems, Abingdon, UK), IL-6,
IL-8, IL-10, IFN-γ (Sanquin, Amsterdam, the Netherlands), and IFN-α, IFN-β (PBL
Interferon Source, Piscataway, USA) was measured in cell culture supernatants using
enzyme-linked immunosorbent assay (ELISA) according to the instructions of the
manufacturer.
SNP selection
DNA was isolated using the Gentra Pure Gene Blood kit (Quiagen, Venlo, The
Netherlands), according to the protocol of the manufacturer. Illumina Immunochip is a
custom designed High-Density array to densely genotype 186 loci associated with 12
different autoimmune or inflammatory diseases reaching genome-wide association study
Smeekens et al. Page 8
Nat Commun. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
significance threshold (P<5×10−8)14. The candidemia cohort and volunteers DNA samples
were genotyped on this Immunochip Illumina platform. Only SNPs in 11 of the 101-gene
dataset identified earlier were studied, as the other genes were not represented on the
Immunochip. We selected tag-SNPs (Supplementary Table S3) at each region that are
located within ± 250 kb of the locus by employing Haploview44 and we excluded SNPs with
r2 ≥ 0.8 from association analysis.
Statistical analysis
Analyses were performed using PLINKv1.0745, 46. We performed Multidimensional scaling
(MDS) analysis to reveal genetic background of cases and controls in Candidemia cohort
(Supplementary Fig. S8). The association between tag-SNPs and Candidemia susceptibility
was tested by logistic regression with the first four components from MDS analysis as
covariates. The correlation between cytokine levels and genotypes was tested by Wilcoxon
rank sum test using R. P-values less than 0.05 was considered significant.
Real-time PCR
Two million freshly isolated PBMCs were incubated with various stimuli as described
above. After 24 hours of incubation at 37°C, total RNA was extracted in 800 μl of TRIzol
reagent (Invitrogen, Breda, The Netherlands). Isolated RNA was reverse-transcribed into
complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was
performed using a 7300 Real-Time PCR system (Applied Biosystems, Lennik, Belgium).
Primer sequences for human IFN-β: sense: 5′- ATG-ACC-AAC-AAG-TGT-CTC-CTC-
C-3′ and antisense: 5′- GGA-ATC-CAA-GCA-AGT-TGT-AGC-TC-3′; IRF9: sense 5′-
GAT-ACA-GCT-AAG-ACC-ATG-TTC-CG-3′and antisense: 5′- TGA-TAC-ACC-TTG-
TAG-GGC-TCA-3′; IRF7: sense: 5′- GCT-GGA-CGT-GAC-CAT-CAT-GTA-3′ and
antisense: 5′- GGG-CCG-TAT-AGG-AAC-GTG-C-3′; ISG15: sense: 5′- CGC-AGA-TCA-
CCC-AGA-AGA-TCG-3′ and antisense: 5′- TTC-GTC-GCA-TTT-GTC-CAC-CA-3′;
IFI44: sense: 5′- ATG-GCA-GTG-ACA-ACT-CGT-TTG-3′ and antisense: 5′- GCA-GGA-
TCT-TTC-GTG-CAA-CC-3′; IFI44L: sense: 5′- AGG-GAA-TCA-TTT-GGC-TCT-GTA-
GA-′3 and antisense: 5′- AGC-CGT-CAG-GGA-TGT-ACT-ATA-AC-3′; IRF3: sense: 5′-
AGA-GGC-TCG-TGA-TGG-TCA-AG-3′ and antisense: 5′-AGG-TCC-ACA-GTA-TTC-
TCC-AGG-3′; IRF5: sense: 5′-GGG-CTT-CAA-TGG-GTC-AAC-G-3′ and antisense: 5′-
GCC-TTC-GGT-GTA-TTT-CCC-TG-3′. B2M was used as a reference gene, for which the
primers were: 5- ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5- CCA-AAT-
GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 minutes at
50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15
seconds, and 60°C for 1 minute.
RNA sequencing
RNA sequencing experiments were performed on 4 hour unstimulated and C. albicans-
stimulated PBMC from three healthy controls and two CMC patients. Total RNA was
isolated as described above. The RNA integrity (RNA integrity score ≥ 7) was measured on
the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA) using an Agilent RNA 6000 Pico
Chip according to the manufacturer’s instructions. Enrichment of mRNA was done using the
MicroPoly(A)Purist Kit (Ambion, Life Technologies, Foster City, USA) according to
manufacturer’s instructions, starting with 5μg of total RNA and using two rounds of
Oligo(dT) selection. Whole transcriptome library preparation was performed using the
SOLiD Total RNA-Seq Kit (STaR Kit, Life Technologies) and the corresponding low input
amount protocol (version July 2011, Life Technologies). In brief, 25ng high quality poly(A)
RNA was fragmented by RNAse III digestion, cleaned up using the PureLink RNA Micro
Kit (Invitrogen, Life Technologies) and checked for quantity and size-distribution on a
Agilent 2100 Bioanalyzer. RNA adapters were hybridized and ligated to the fragmented
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RNA, followed by reverse transcription. After purification and size-selection of cDNA using
Agencourt AMPure XP Reagent beads, the cDNA was amplified and used as input for the
SOLiD system bead preparation using the SOLiD Easy bead system (E120 scale). Paired-
end sequencing (50+25 bases) was performed on one flowcell of a 5500XL sequencer (Life
Technologies) For each sample deep sequencing was performed resulting in a sequencing
depth ranging from 75.6 million to 105.5 million paired-end reads. Paired-end colorspace
reads were mapped against the human genome (hg19) using Tophat (version 1.4.1)47. To
increase mapping performance a GTF-file containing the exon boundries of all known
RefSeq genes (25,024 genes) was supplied to Tophat and the insert size was set to 110
bases. For all genes FPKM (Fragments per Kilobase per Million mapped reads) values were
calculated using Cufflinks (version 2.0.0)48. Further statistical analyses was done using
Partek® Genomic Suite software (version 6.6, build 6.12.0109, Partek Inc., St. Louis, USA).
Fold changes and p-values were calculated for each gene by performing a multifactorial
Analysis of Variance (ANOVA) on log2 (with an offset of 1.0) transformed FPKM
expression values. Factors included in the ANOVA model were group (patient or control),
treatment (stimulation status), individual (data from same individual), and the interaction
between group and treatment. Fold changes for the heatmaps were calculated for each
individual by dividing the FPKM expression values of the C. albicans stimulated sample by
the unstimulated (RPMI) sample. Fold changes with values below 1 were replaced by the
negative of the inverse. A gene list containing 101 differentially expressed transcripts known
from the expression array was used to select genes for further downstream analysis. Of this
list, 10 transcripts were not considered; 7 because another isoform was already used for
FPKM calculations, and 3 hypothetical proteins without concordant refseq genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transcriptional responses to Candida
(a) K-means clustering identifies shared and specific gene signatures in response to infection
or stimulation. For example, clusters 21 and 25 indicate common inflammatory genes
(details in Supplementary Fig. S2) that are significantly differentially induced genes
(Benjamini-Hochberg-adjusted-p<0.05, fold-change>2) in response to Borrelia burgdorferi,
Candida albicans, E.coli-derived LPS, and Mycobacterium tuberculosis (M.tb), compared to
RPMI stimulations (Untreated), while clusters 7, 11 and 20 identify Candida-dominant
response genes. Signal-to-noise ratio relative to untreated is shown in the heatmap. (b)
Using feature selection, naïve Bayes classifier and 10-fold cross-validation, a 101-transcript
feature set was identified from 693 differentially expressed transcripts shown in (a), which
distinguishes Candida from the other stimulants and an area under the ROC (Receiver
operating characteristic) curve of 97.8%, indicating a high discriminative value. The
expression profile (Z-transformed) of this feature set is displayed. (c) Principal component
analysis (PCA) of the Candida-response signature. Data from each individual sample is
plotted along the three main principal components (PC1, PC2, PC3). The three main
principal components account for 45% of the total variance in gene expression. Samples
from the various stimulations and infections are color coded as follows: Candida albicans
(2h: bright red; 24 hr: dark red), Borrelia burgdorferi (Green), E.coli-derived LPS (Blue),
Mycobacterium tuberculosis (M.tb) (Purple) and untreated (Yellow). (d) Enrichment
analysis (MetaCore pathways) of the 101-transcript feature set reveals a striking enrichment
of the interferon (IFN) signaling pathway. Supplementary Table S2 displays all the
signaling/biological processes shown and their enrichment p-values.
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Figure 2. SNPs of type I IFN responsive genes are associated with susceptibility to Candidemia
Regional association plots, at (a) STAT1 region (b) CCL8/CCL13 region (c) SP110 region
and (d) PSMB8 region, showing chromosome position in the x-axis and the–log of logistic P
values for each SNP in the y-axis. Blue diamond indicates the top P value; while orange and
yellow diamonds indicates r2 ranges of 0.6 to 0.8 and 0.4 to 0.59, respectively with the top
associated SNP. SNP names shown are as in dbSNP130 where available. Otherwise, the
Illumina Immunochip manifest name is shown. For example 1kg_17_29697448 indicates the
location of SNP on chromosome 17 at position 29697448 (hg18).
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Figure 3. SNPs of type I IFN responsive genes are associated with Candida-induced cytokine
levels
Correlation plots showing the association between genotypes in the x-axis and cytokines
levels in the y-axis. Association between (a) TNF-alpha levels and genotypes at IRF1 SNP
rs2548997, (b) IL-10 levels and genotypes at IRF1 SNP rs1124211, (c) TNF-alpha and
genotype at STAT1 SNP rs2280234 and (d) IL-6 levels and genotypes at STAT1 SNP
rs41511150.
Smeekens et al. Page 15
Nat Commun. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Type I IFNs skew cytokine production from a Th1 towards a Th17 response
(a) 5 · 105 PBMC in a volume of 200 μL, were stimulated for seven days, in the presence of
10% human pooled serum, with live Candida albicans (1 · 106/mL), in duplo. IFN-α and
IFN-β were measured in cell culture supernatants using ELISA. (b) 5 · 105 PBMC in a
volume of 200 μL, were stimulated for one and two days, with heat-killed Candida albicans
(1 · 106/mL), in the absence of presence of anti-IFN-α/βR2, in duplo. IFN-γ, IL-1β and
TNF-α were measured in cell culture supernatants using ELISA. (c) 5 · 105 PBMC in a
volume of 200 μL, were stimulated for two and seven days, with heat-killed Candida
albicans (1 · 106/mL), in the absence of presence of IFN-α or IFN-β, in duplo. When cells
were cultured for seven days, this was done in the presence of 10 % human pooled serum.
IFN-γ, IL-17 and IL-22 were measured in cell culture supernatants using ELISA. (a,b,c)
After stimulation, supernatants were pooled and stored at −20 C° until further assayed. Data
were analyzed using the Wilcoxon signed rank test. Data are presented as mean + SEM.
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Figure 5. Expression of type I IFN pathway genes in patients with a STAT1 mutation
Reduced expression of type I IFN pathway genes in patients with a STAT1 mutation (n = 2,
with patients measured twice), and healthy controls (n = 8). 5 · 105 PBMC in a volume of
200 μL, were stimulated for 24 hours, with RPMI, E. coli-derived LPS (10 ηg/mL), heat-
killed Candida albicans (1 · 106/mL), or heat-killed Mycobacterium tuberculosis (1 μg/mL).
mRNA was isolated from cell lysates using TRIzol. Transcription of IFN-β, IRF3, IRF9,
IRF5, IRF7, ISG15, IFI44 and IFI44L was measured using qPCR. Data are presented as
mean + SEM.
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Figure 6. Heatmap of response of CMC patients and controls to Candida albicans in vitro
stimulation
In this analysis the standardized fold change gene expression in stimulated vs. unstimulated
cells was calculated. The scale of this heatmap is given as standardized log2 fold change
with a range from −1.8 (blue) to +1.8 (red).
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